Used as a key intermediate in the synthesis of non-steroidal anti-inflammatory drugs (NSAIDs), particularly in the production of lumiracoxib, a selective COX-2 inhibitor. Its structure allows for effective binding and inhibition of inflammatory pathways, making it valuable in developing analgesic and antipyretic medications. The compound’s sulfonyl and carboxylic acid groups contribute to solubility and pharmacokinetic properties, enhancing drug efficacy. It is also employed in research for designing new anti-arthritic agents due to its favorable metabolic stability and target specificity.